research Alopecia areata following COVID-19 vaccine: a systematic review
Alopecia areata after COVID-19 vaccination is rare but important to recognize for timely treatment.
Search
for
Sort by
Research
270-300 / 1000+ results
research Topical tofacitinib for the treatment of alopecia areata affecting facial hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research What is behind the ‘swarm of bees’ in alopecia areata
Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research Mechanisms of autophagy and their implications in dermatological disorders
Targeting autophagy can help treat skin disorders like vitiligo and atopic dermatitis.
research Frontal fibrosing alopecia: a disease fascinating for the researcher, disappointing for the clinician and distressing for the patient
Frontal Fibrosing Alopecia is a poorly understood condition that is hard to treat and causes distressing hair loss.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib treatment for hair loss may worsen acne.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
research Management of folliculitis decalvans: The EADV task force on hair diseases position statement
Control inflammation and prevent further hair loss in folliculitis decalvans using medications and therapies.
research II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
research Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
research Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
Childhood Alopecia Areata causes hair loss and requires varied treatments, with psychological support being crucial.
research Global burden of alopecia areata from 1990 to 2019 and emerging treatment trends analyzed through GBD 2019 and bibliometric data
Alopecia areata affects women and young adults most, with low SDI regions seeing the highest increase, and new treatments like JAK inhibitors are being explored.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research What’s New in Hair Loss
New treatments for hair loss show promise, but require more research on long-term effects and proper dosing.
research Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
research Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review
Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
research Hypohidrotic Ectodermal Dysplasia with c.28delG Mutation in Ectodysplasin A Gene and Severe Atopic Dermatitis Treated Successfully with Tofacitinib
Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.
research A Potential Role for IL-4 and IL-13 in an Alopecia Areata–Like Phenotype: A Clinical Perspective
IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.
research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
research Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
Experts recommend personalized treatment plans for alopecia areata, using corticosteroids and minoxidil for mild cases, and stronger medications for severe cases.
research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
Ruxolitinib cream may help treat severe hair loss in children.
research Inhibition of T-cell activity in alopecia areata: recent developments and new directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.